S
Scinai Immunotherapeutics Ltd.
SCNICIK 0001611747NasdaqNon-AcceleratedBiological Products, (No Diagnostic Substances)L3ILFY ends Dec 31
Period
FY 2025
Revenue
$1.31M
Net Income
$-8.31M
Total Assets
$11.63M
Equity
$8.10M
Shares Out
13.87B
Op. Cash Flow
$-6.03M
Business
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company developing nanosized VHH antibody fragments (NanoAbs) and operating a boutique CDMO. Its main offerings include a pipeline of NanoAb therapeutic candidates for inflammation and immunology indications, an option to acquire PC111 (a monoclonal antibody for dermatological disorders), and contract development and GMP/non‑GMP manufacturing services. The company is organized into two business units: an R&D unit focused on NanoAbs and a CDMO unit branded Scinai Bioservices. It collaborates with academic partners in Germany, provides services to biotech clients globally, and maintains manufacturing capacity in Jerusalem with a U.S. subsidiary for CDMO operations.
Summary from filing dated 2025-05-07
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|
| Research and development. | 6 | 3 | |
| Marketing, general and administrative | 5 | 8 | |
| Other income | — | −12,000 | |
| Total operating loss | 11 | 11 | |
| Financial income, net | −5 | −3 | |
| Net loss | 6 | 8 | |
| Net loss per share attributable to ordinary shareholders, basic (in Dollars per share) | −0.01 | −0.02 | |
| Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic (in Shares) | 754 | 565 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|
| Cash and cash equivalents | 14 | 17 | |
| Restricted cash | 140,000 | 143,000 | |
| Prepaid expenses and other receivables | 155,000 | 326,000 | |
| Total current assets | 14 | 18 | |
| Property, plant and equipment, net | 11 | 12 | |
| Operating lease right-of-use assets | 1 | 2 | |
| Total non-current assets | 13 | 14 | |
| Total assets | 27 | 32 | |
| Trade payables | 716,000 | 999,000 | |
| Operating lease liabilities | 382,000 | 375,000 | |
| Other payables | 1 | 1 | |
| Total current liabilities | 2 | 2 | |
| Warrants liability | 5 | — | |
| Loan from others | 20 | 27 | |
| Non-current operating lease liabilities | 1 | 1 | |
| Total non-current liabilities | 26 | 29 | |
| Ordinary shares of no par value: Authorized: 20,000,000,000 shares at December 31, 2022 and 1,800,000,000 at December 31, 2021; Issued and outstanding 989,290,784 shares at December 31, 2022 and 739,048,544 shares at December 31, 2021 | — | — | |
| Additional paid-in capital | 116 | 113 | |
| Accumulated deficit | −116 | −110 | |
| Accumulated other comprehensive loss | −2 | −2 | |
| Total shareholders equity (deficit) | −2 | 982,000 | |
| Total liabilities and shareholders equity | 27 | 32 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|
| Depreciation of property, plant and equipment | 562,000 | 471,000 | |
| Expense of in-process research and development | 209,000 | — | |
| Financial income related to loan from others | −4 | −3 | |
| Share-based compensation | 2 | 3 | |
| Decrease in other receivables | 140,000 | 59,000 | |
| Changes in operating lease right-of-use assets | 153,000 | 148,000 | |
| Increase (decrease) in trade payables | −175,000 | 3,000 | |
| Changes in operating lease liabilities | −156,000 | −150,000 | |
| Increase in other payables | 309,000 | 644,000 | |
| Net cash used in operating activities | −7 | −7 | |
| Purchase of property, plant and equipment | −836,000 | −139,000 | |
| Net cash used in investing activities | −836,000 | −139,000 | |
| Proceed from issuance of warrants | 6 | — | |
| Proceeds from issuance of shares, net | 932,000 | 21 | |
| Net cash provided by financing activities | 7 | 21 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | −2 | 575,000 | |
| Increase (decrease) in cash, cash equivalents and restricted cash | −3 | 14 | |
| Interest | 916,000 | — | |
| Exercise of warrants liability to equity | 250,000 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro